Format

Send to

Choose Destination
Br J Dermatol. 2001 Mar;144(3):587-9.

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.

Author information

1
Departments of Dermatology and Medicine III, University of Erlangen, Hartmannstr. 14, D-91052 Erlangen, Germany.

Abstract

BACKGROUND:

In inflamed skin, keratinocytes and inflammatory cells both produce large amounts of tumour necrosis factor (TNF) -alpha, a cytokine with broad effects that are relevant to inflammation. Blockade of this proinflammatory cytokine by a monoclonal anti-TNF-alpha antibody might be effectively used in the treatment of inflammatory skin diseases.

OBJECTIVES:

To gather information about the efficacy of an anti-TNF-alpha antibody (infliximab) in the treatment of skin lesions of psoriatic arthritis.

METHODS:

Six patients with progressive joint disease and psoriatic skin lesions unresponsive to methotrexate therapy were treated with anti-TNF-alpha antibody. The Psoriasis Area and Severity Index was determined before and 10 weeks after initiation of therapy.

RESULTS:

Improvement of psoriatic skin lesions was observed in all patients. In addition, a marked improvement of the joint disease was noted.

CONCLUSIONS:

Therapy with anti-TNF-alpha antibody may be an effective treatment regimen for both psoriatic arthritis and psoriatic skin lesions.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center